Profile data is unavailable for this security.

About the company

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

  • Revenue in GBP (TTM)19.30bn
  • Net income in GBP2.00bn
  • Incorporated1992
  • Employees61.50k
  • Location
    AstraZeneca PLC- Legal Department, 2 Kingdom StreetLONDON W2 6BDUnited KingdomGBR
  • Phone+44 20 7304 5000
  • Fax+44 20 7604 8151
  • Websitehttp://www.astrazeneca.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Actelion Ltd2.31bn681.05m24.04bn2.50k35.5317.6131.3710.406.286.2821.2212.671.112.235.18--32.6712.8644.8617.0291.3889.3329.3918.801.91--0.0036.584.451.18-7.067.16-20.3713.40
Shire PLC7.52bn332.15m39.62bn5.55k61.211.6629.115.270.71580.414210.8626.430.21341.104.741,355,589.000.948316.511.0921.9267.6285.504.4429.440.56924.480.44347.766.5513.08-59.2617.86-19.0215.02
AstraZeneca plc19.25bn1.99bn54.49bn61.50k27.365.1614.332.831.571.5715.218.350.40591.784.21312,957.704.098.195.7011.4582.7380.7010.0616.480.67914.120.542578.91-6.93-5.78129.12-18.905.031.89
GlaxoSmithKline plc26.59bn301.00m75.93bn101.19k257.92546.4037.522.860.060.065.460.02830.47031.724.09262,757.900.560712.630.865419.4067.0169.951.1921.150.67488.950.828975.363.99-3.37205.5938.813.064.24
Sanofi SA34.35bn4.20bn97.70bn115.63k23.46--15.802.843.223.2726.46--------297,057.00--4.56--5.3069.1168.4012.2513.16--20.15--79.698.940.48023.23-4.2010.773.23
Novo Nordisk A/S111.08bn37.48bn500.73bn42.61k16.8815.6412.344.5114.7414.7443.6815.911.291.257.462,733,501.0043.4535.2981.1255.7484.8183.2433.7429.450.897440.940.010946.7521.5312.1731.6419.3410.4526.19
Data as of Jan 20 2017. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

22.22%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Jan 201653.17m4.20%
Wellington Management Co. LLPas of 01 Jan 201736.38m2.88%
Legal & General Investment Management Ltd.as of 01 Jan 201735.93m2.84%
The Vanguard Group, Inc.as of 01 Jan 201732.14m2.54%
Woodford Investment Management LLPas of 01 Jan 201725.84m2.04%
Norges Bank Investment Managementas of 01 Jan 201722.83m1.81%
Invesco Asset Management Ltd.as of 01 Jan 201721.12m1.67%
Threadneedle Asset Management Ltd.as of 01 Jan 201718.68m1.48%
BlackRock Advisors LLCas of 01 Jan 201717.95m1.42%
Capital Research & Management Co. (World Investors)as of 31 Jan 201617.00m1.34%
More ▼
Data from 31 Dec 2015 - 30 Sep 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.